The Kleresca line of products are being commercialized for in-office treatments and designed to target specific dermatological conditions, primarily being moderate to severe acne. Other applications include Lumixa for cosmetic applications. Click on Dermatology to see how Kleresca or Lumixa can potentially help you.
LumiHeal is an early-stage product with applications in wound care, including scar management. It which impacts the three (3) critical phases of healing: inflammation, proliferation and remodeling. LumiHeal is an active solution that delivers high response rates and provides an excellent safety profile.
PERIO-1 is a late-stage clinical asset with applications as an in-office adjunct to scaling and root planing (SRP), for the treatment of moderate to severe chronic periodontitis. Clinical data has shown the application facilitates periodontal pocket debridement, improves periodontal pocket and gum reattachment.
Phovia is an early-stage commercial asset globally partnered with Vetoquinol based in Lure, France. Initial indications are for Pyoderma as part of their companion animal products line. Please visit Vetoquinol’s website for further information and updates relating to the Phovia program.